After a prolonged period of decline, Inovio started to show signs of life in November 2019.
It has soared from under $2.00 per share at the time, to a 52-week high of $33.79 per share by June 2020.
After another downward trend it is once again jumping on news of the FDA signing off on its Phase 2 COVID-19 trial.
READ FULL ARTICLE HERE